ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

– Data establishes miR-23b as a disease-modifying target in DM1 and demonstrates enhanced muscle delivery and functional benefit of ATX-01 – VALENCIA, Spain, Feb. 25, 2026 /PRNewswire/ -- Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for...